Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts give Nkarta a consensus rating of "Hold" (1 sell, 1 hold, 3 buy) with an average 12‑month price target of $11.33.
• Shares trade around $2.77 (market cap ~$197M) after Nkarta missed quarterly EPS at -$0.37 vs. -$0.32 expected, and analysts forecast about -$1.51 EPS for the year.
• Institutional investors own roughly 80.54% of the stock with multiple funds adding positions, and Nkarta is a clinical‑stage biotech developing off‑the‑shelf CAR‑NK therapies, led by NKX019.

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $11.3333.

NKTX has been the subject of a number of research reports. Needham & Company LLC raised their target price on Nkarta from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Mizuho reduced their price target on shares of Nkarta from $14.00 to $12.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of Nkarta in a report on Friday, March 27th. Finally, Wall Street Zen cut shares of Nkarta from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th.

Nkarta Price Performance

NASDAQ NKTX opened at $2.77 on Friday. The firm has a market cap of $197.47 million, a PE ratio of -1.98 and a beta of 0.66. Nkarta has a one year low of $1.63 and a one year high of $3.65. The stock's 50 day simple moving average is $2.49 and its 200 day simple moving average is $2.19.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.05). As a group, equities analysts expect that Nkarta will post -1.51 earnings per share for the current year.

Institutional Trading of Nkarta

Hedge funds and other institutional investors have recently modified their holdings of the stock. GSK plc acquired a new position in Nkarta during the 4th quarter worth $5,829,000. Jane Street Group LLC boosted its position in Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after buying an additional 852,559 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Nkarta in the 3rd quarter valued at $1,549,000. Monaco Asset Management SAM increased its stake in shares of Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company's stock valued at $4,712,000 after buying an additional 576,022 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Nkarta by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company's stock worth $3,149,000 after acquiring an additional 556,945 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.